Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men

Journal of Internal Medicine

Volumn 254, Issue 1, 2003, Pages 76-84

  Dell'Omo, G ^a   Giorgi, D ^a   Di Bello, V ^a   Mariani, M ^a   Pedrinelli, Roberto ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Albuminuria; Essential hypertension; Left ventricular hypertrophy; Microalbuminuria

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; EVALUATION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

ALBUMINURIA; BLOOD PRESSURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0038009861     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01155.x     Document Type: Article

References (39)

1. Pedrinelli R, Dell'Omo G, Penno G, Mariani M. Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease. Vasc Med 2001; 6: 257-64.
2. Pedrinelli R, Dell'Omo G, Di Bello V, Pontremoli R, Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 2002; 16: 79-89.
3. Yudkin JS, Forrest RD, Jackson C. Microalbuminuria as predictor of vascular disease in nondiabetic subjects. Lancet 1988; 2: 530-3.
4. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992-7.
5. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35: 898-903.
6. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 25: 421-6.
7. Roest M, Banga JD, Janssen WM et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001; 103: 3057-61.
8. Pedrinelli R, Di Bello VD, Catapano G et al. Microalbuminuria is a marker of left ventricular hypertrophy but not hyperinsulinemia in nondiabetic atherosclerotic patients. Arterioscler Thromb 1993; 13: 900-6.
9. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334-41.
10. O'Brien E, Coats A, Owens P et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. Br Med J 2000; 320: 1128-34.
11. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25: 1056-62.
12. Verdecchia P, Porcellati C, Zampi I et al. Asymmetric left ventricular remodeling due to isolated septal thickening in patients with systemic hypertension and normal left ventricular masses. Am J Cardiol 1994; 73: 247-52.
13. de Simone G, Devereux RB, Roman MJ et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 1994; 23: 1444-51.
14. Ganau A. Devereux RB, Roman MJ et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550-8.
15. Ilercil A, O'Grady MJ, Roman MJ et al. Reference values for echocardiographic measurements in urban and rural populations of differing ethnicity: the Strong Heart Study. J Am Soc Echocardiogr 2001; 14: 601-11.
16. Verdecchia P. Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension 2000; 35: 844-51.
17. Verdecchia P, Schillaci G, Guerrieri M et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528-36.
18. Palatini P, Mormino P, Santonastaso M et al. Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: results from the HARVEST study. Hypertension 1998; 31: 57-63.
19. Wachtell K, Olsen MH, Dahlöf B et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002; 20: 405-12.
20. Gerstein HC, Mann JF, Pogue J et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. Diabetes Care 2000; 23 (Suppl. 2): B35-9.
21. Redon J, Liao Y, Lozano JV, Miralles A, Pascual JM, Cooper RS. Ambulatory blood pressure and microalbuminuria in essential hypertension: role of circadian variability. Am J Hypertension 1994; 12: 947-53.
22. Gatzka CD, Reid CM, Lux A, Dart AM, Jennings GL. Left ventricular mass and microalbuminuria: relation to ambulatory blood pressure. Hypertension Diagnostic Service Investigators. Clin Exp Pharmacol Physiol 1999; 26: 514-6.
23. Pedrinelli R, Dell'Omo G, Penno G et al. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension 2000; 35: 48-54.
24. Wachtell K, Palmieri V, Olsen MH et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002; 143: 319-26.
25. Schillaci G, Vaudo G, Pasqualini L, Reboldi G, Porcellati C, Verdecchia P. Left ventricular mass and systolic dysfunction in essential hypertension. J Hum Hypertens 2002; 16: 117-22.
26. Quinones MA, Greenberg BH, Kopelen HA et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 2000; 35: 1237-44.
27. Gerdts E, Oikarinen L, Palmieri V et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2002; 39: 739-43.
28. Pontremoli R, Ravera M, Bezante GP et al. Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. J Hypertens 1999; 17: 993-1000.
29. Dell'Omo G, Penno G, Bertini A et al. The association between high-normal albuminuria and risk factors for cardiovascular and renal disease in hypertensive men. Am J Kidney Dis 2002 40: 1-8.
30. Matsuo H. Discovery of a natriuretic peptide family and their clinical application. Can J Physiol Pharmacol 2001; 79: 736-40.
31. McMurray J, Seidelin PH, Howey JE et al. The effect of atrial natriuretic factor on urinary albumin and beta 2-microglobulin excretion in man. J Hypertens 1988; 6: 783-6.
32. Vervoort G, Hertenberg F, Wetzels JF et al. Influence of angiotensin converting enzyme inhibition and angiotensin II type I receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers. J Hypertens 1998; 16: 245-50.
33. Nishikimi T, Yoshihara F, Morimoto A et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28: 22-30.
34. Hishiki S, Tochikubo O, Miyajima E et al. Circadian variation of urinary microalbumin excretion and ambulatory blood pressure in patients with essential hypertension. J Hypertens 1998; 16: 2101-8.
35. Ellekilde G, Holm J, von Eyben FE, Hemmingsen L. Above-normal urinary excretion of albumin and retinol-binding protein in chronic heart failure. Clin Chem 1992; 38: 593-4.
36. Eiskjaer H, Bagger JP, Mogensen CE, Schmitz A, Pedersen EB. Enhanced urinary excretion of albumin in congestive heart failure: effect of ACE-inhibition. Scand J Clin Lab Invest 1992; 52: 193-9.
37. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3A-9A.
38. Verdecchia P, Reboldi G, Schillaci G et al. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 1999; 100; 1802-7.
39. Nestler JE, Barlascino Go Tetrault GA, Fratkin MJ, Clore JN, Blackward WG. Increased transcapillary escape rate of albumin in nondiabetic men in response to hyperinsulinemia. Diabetes 1990; 39: 1212-7.